Pyrazinamide microbiology

Revision as of 01:00, 4 January 2014 by Chetan Lokhande (talk | contribs) (Created page with "__NOTOC__ {{Pyrazinamide }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIK...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Pyrazinamide
PYRAZINAMIDE® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]



[1]


References

  1. "PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIKART, INC.]".

Adapted from the FDA Package Insert.